drugset / Trial / NCT04584242
Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes
RandomizedParallel-groupOpen-labelTreatment
Summary
The clinical study determines the effect of Evogliptin in patients with type 2 diabetes mellitus and chronic hepatitis B to confirm the improvement of hepatic fibrosis.
Timeline
- Start
- 2020-09-03
- Primary completion
- 2022-05
- Completion
- 2022-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Evogliptin | Small molecule | 5 mg | Oral |
| Subject | Pioglitazone | Small molecule | 30 mg | Oral |